New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.
New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.
Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.
DIET VIDEO + ARTICLE: Healthy? Normal blood sugar? No diabetes? Even so, find out how the more sugar you eat, the less memory you get.
ASTONISHING VIDEO & ARTICLE: Dementia-risk was tested for 17 sugar levels in 2000 people. Each higher level bumped up the risk, without exception. See why researchers found these results so compelling.
VIDEO: Men and women living into their nineties are the fastest growing segment in the US population. What determines who will make it into their 90s, and in what condition? The “90+” research study is hoping to find out. Learn more.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
